- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05338775
Een studie van Talquetamab en Teclistamab, elk in combinatie met een geprogrammeerde celdoodreceptor-1 (PD-1)-remmer voor de behandeling van deelnemers met gerecidiveerd of refractair multipel myeloom (TRIMM-3)
Een fase 1b-studie van bispecifieke T-celomleidingsantilichamen in combinatie met Checkpoint-inhibitie voor de behandeling van deelnemers met recidiverend of refractair multipel myeloom
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Uitgebreide toegang
Contacten en locaties
Studie Locaties
-
-
-
Dresden, Duitsland, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Hamburg, Duitsland, 20246
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Duitsland, 69120
- Universitaetsklinikum Heidelberg
-
Würzburg, Duitsland, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Montpellier, Frankrijk, 34295
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Frankrijk, 44093
- CHU de Nantes hotel Dieu
-
Poitiers, Frankrijk, 86021
- CHU Poitiers - Hopital la Miletrie
-
Toulouse, Frankrijk, 31059
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
-
-
-
Badalona, Spanje, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Spanje, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, Spanje, 31008
- Clinica Univ. de Navarra
-
Salamanca, Spanje, 37007
- Hosp Clinico Univ de Salamanca
-
-
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Colorado Blood Cancer Institute
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Verenigde Staten, 10011
- The Blavatnik Family Chelsea Medical Center at Mount Sinai
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest Baptist Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt Ingram Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Participants with relapsed or refractory disease that are not a candidate for available therapy with established clinical benefit
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); b) Urine M-protein level >= 200 milligrams (mg) per 24 hours; c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams/deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Prior antitumor therapy within 21 days prior to the first dose of study treatment (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene -modified adoptive cell therapy or autologous stem cell transplant within 3 months)
- Prior therapy with PD-1 inhibitors, allogeneic stem cell transplant or solid organ transplant
- Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis
- Active Central Nervous System (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Live, attenuated vaccine within 4 weeks before the first dose of study treatment
- Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia [any grade] or peripheral neuropathy to Grade <= 2)
- Received a cumulative dose of corticosteroids equivalent to >= 140 milligrams (mg) of prednisone within the 14-day period before the start of study treatment administration
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1: Dose Escalation
Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
|
Experimenteel: Part 2: Dose Expansion
Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Tijdsspanne: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years 5 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
Tijdsspanne: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event. |
Up to 2 years 5 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Tijdsspanne: Up to 2 years 5 months
|
Number of participants with abnormalities in clinical laboratory assessments (serum chemistry and hematology) will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Dose-Limiting Toxicity (DLTs)
Tijdsspanne: Up to 2 years 5 months
|
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 2 years 5 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Response Rate (ORR)
Tijdsspanne: Up to 2 years 5 months
|
ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria. |
Up to 2 years 5 months
|
|
Very Good Partial Response (VGPR) or Better Response Rate
Tijdsspanne: Up to 2 years 5 months
|
VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Complete Response (CR) or Better Response Rate
Tijdsspanne: Up to 2 years 5 months
|
CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Stringent Complete Response (sCR) Rate
Tijdsspanne: Up to 2 years 5 months
|
sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Duration of Response
Tijdsspanne: Up to 2 years 5 months
|
Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG 2016 criteria or death due to any cause, whichever occurs first. |
Up to 2 years 5 months
|
|
Time to Response
Tijdsspanne: Up to 2 years 5 months
|
Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better. |
Up to 2 years 5 months
|
|
Serum Concentrations of Talquetamab
Tijdsspanne: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Talquetamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of Teclistamab
Tijdsspanne: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Teclistamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of PD-1 Inhibitor
Tijdsspanne: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of PD-1 inhibitor using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Talquetamab Antibodies
Tijdsspanne: Up to 2 years 5 months
|
Number of participants with anti-talquetamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Teclistamab Antibodies
Tijdsspanne: Up to 2 years 5 months
|
Number of participants with anti-teclistamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-PD-1 Inhibitor Antibodies
Tijdsspanne: Up to 2 years 5 months
|
Number of participants with anti-PD-1 inhibitor antibodies will be reported. |
Up to 2 years 5 months
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Janssen Research and Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CR109168
- 2021-005073-22 (EudraCT-nummer)
- 64407564MMY1005 (Andere identificatie: Janssen Research & Development, LLC)
- 2022-502681-24-00 (Register-ID: EUCT number)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .